Page last updated: 2024-11-12

magainin 2 peptide, xenopus

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

magainin 2 peptide, Xenopus: from skin of Xenopus laevis; 23-amino acid sequence given in first source; differs from magainin 1 by substitution of Lys instead of Gly at position 10 & Asn instead of Lys at position 22; also used to prevent development of malarial oocysts in mosquito vector; Z-12 is magainin 2 with Lys and Phe residues replaced with their respective D-isomers; homologue of the Xenopus laevis cement; GenBank AF004262 (mouse), AF007791, AF038451-2 (human) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16130189
MeSH IDM0150987

Synonyms (15)

Synonym
nh2-gly-ile-gly-lys-phe-leu-his-ser-ala-lys-lys-phe-gly-lys-ala-phe-val-gly-glu-ile-met-asn-ser-cooh
gly-ile-gly-lys-phe-leu-his-ser-ala-lys-lys-phe-gly-lys-ala-phe-val-gly-glu-ile-met-asn-ser
magainin 2 ,
108433-95-0
magainin ii
magainin-2
z-12 peptide
mag-2
magainin i, 10-l-lysine-22-l-asparagine-
magainin 2 peptide, xenopus
magainin-2, xenopus
magainin ii, xenopus
magainin 2, xenopus
DTXSID50148547
AKOS040764010

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"Lactobacillus plantarum has been exposed to mild heat at temperatures between 48 and 56 degrees C in combination with low concentrations of the lantobiotic nisin in different sequential set-ups."( Synergistic antibacterial action of heat in combination with nisin and magainin II amide.
Coote, PJ; ter Steeg, PF; Ueckert, JE, 1998
)
0.3
"The in-vitro activity of cecropin P1, magainin II, indolicidin and ranalexin alone and in combination with macrolides and dihydrofolate reductase inhibitors (DHFRs) was investigated against six clinical isolates of Pneumocystis carinii."( In-vitro activity of lytic peptides alone and in combination with macrolides and inhibitors of dihydrofolate reductase against Pneumocystis carinii.
Barchiesi, F; Cirioni, O; Giacometti, A; Scalise, G, 1998
)
0.3
"The in vitro activities of magainin II, nisin, and ranalexin alone and in combination with other antimicrobial agents against six clinical isolates of Rhodococcus equi were investigated by MIC and time-kill studies."( In vitro activities of polycationic peptides alone and in combination with clinically used antimicrobial agents against Rhodococcus equi.
Ancarani, F; Cirioni, O; Del Prete, MS; Fortuna, M; Giacometti, A; Scalise, G, 1999
)
0.3
"The in vitro activity of ranalexin alone and in combination with other cationic peptides, macrolides, rifampin, and rifabutin was investigated against a clinical isolate of Cryptosporidium parvum."( In vitro anticryptosporidial activity of ranalexin alone and in combination with other peptides and with hydrophobic antibiotics.
Barchiesi, F; Cirioni, O; Fortuna, M; Giacometti, A; Scalise, G, 1999
)
0.3
"The in vitro activities of buforin II, cecropin P1, and magainin II, alone and in combination with six clinically used antimicrobial agents, against 12 clinical isolates of Stenotrophomonas maltophilia were investigated."( In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia.
Barchiesi, F; Cirioni, O; Del Prete, MS; Drenaggi, D; Fortuna, M; Giacometti, A; Scalise, G, 2000
)
0.31

Bioavailability

ExcerptReferenceRelevance
" Melittin, while showing little potential as an antimicrobial agent, may have potential in delivery of poorly bioavailable drugs."( Investigation of the cytotoxicity of eukaryotic and prokaryotic antimicrobial peptides in intestinal epithelial cells in vitro.
Maher, S; McClean, S, 2006
)
0.33

Dosage Studied

ExcerptRelevanceReference
" The dose-response curves differed widely for these peptides, making it difficult to rank them into an activity order over the whole concentration range."( Analyses of dose-response curves to compare the antimicrobial activity of model cationic alpha-helical peptides highlights the necessity for a minimum of two activity parameters.
Gerstner, GD; Kulenkampff, J; Rautenbach, M; Vlok, NM; Westerhoff, HV, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (244)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (4.51)18.7374
1990's96 (39.34)18.2507
2000's104 (42.62)29.6817
2010's31 (12.70)24.3611
2020's2 (0.82)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.86 (24.57)
Research Supply Index5.52 (2.92)
Research Growth Index5.38 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews15 (6.02%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other234 (93.98%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]